In this respect of increasing the risk of infection, anifrolumab has a similar incidence as that reported in clinical trials of other drugs used to treat SLE, such as monoclonal antibodies to B-cell activating factor or CD22 (17, 19, 20). This evidence concerns the gene CD22 and infection.